JOHNSON & JOHNSON
JNJNYSETrading Snapshot
- Day Range
- $265.75 – $270.48
- 52-Week Range
- $179.80 – $281.07
- Volume
- $9.36B
- Avg Volume
- $10.93B
- Shares Outstanding
- 2.41B
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $94.19B
- Last Q Revenue
- $25.31B
- P/E Ratio
- 31.4
- P/S Ratio
- 6.7x
- EPS (TTM)
- $8.62
- Dividend Yield
- 1.95%
- Dilution (1yr)
- +0.5%
Why Investors Own JNJ
- ✓High-growth profile — revenue up +25.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
JOHNSON & JOHNSON
JNJ
StockOtter · stockotter.spaceAbout JOHNSON & JOHNSON
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
On October 13, Johnson & Johnson will report its results for the third quarter. As a reminder, its Q2 revenue grew 6.6% year-over-year to $25.31 billion, primarily due to the strong performance of the multiple myeloma po
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in anti-AChR+a
Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years
Three stocks have raised their dividends for over 30 consecutive years through recessions, wars, and market crashes, and one has paid shareholders without interruption for 136 years straight.
How Large Does Your Portfolio Need to Be to Generate $8,350 a Month?
The portfolio size needed to generate a six-figure passive income swings by nearly $2 million depending on one decision, and getting that decision wrong could leave your monthly check vulnerable to a single dividend cut.
Johnson & Johnson's Next Growth Engine Is Taking Shape
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull case or th